
ISPOR Europe 2026

8-11 November 2026 | Vienna | Austria

PORIB presente en ISPOR

ISPOR
Improving healthcare decisions

CLINICAL AND ECONOMIC VALUE OF SELADELPAR IN COMBINATION WITH URSODEOXYCHOLIC ACID FOR THE TREATMENT OF PRIMARY BILIARY CHOLANGITIS IN SPAIN


Clinical and economic value of seladelpar in combination with ursodeoxycholic acid for the treatment of Primary Biliary Cholangitis in Spain

Poster #EE247

Conclusions

Introduction

Objective

Materials and methods

Results

Figure 1. Model structure


Figure 2. Target population

Figure 3. Number of events for each health state by treatment for the cohort of 3,115 patients

Figure 4. Total cost savings for each health state and treatment option for the cohort of 3,115 patients

Grau S, Cantero H, Martín-Escudero V, González-Alonso del Hoyo R, Mareque M

COST-EFFECTIVENESS ANALYSIS OF EXPANDED INFLUENZA VACCINATION COVERAGE WITH LIVE ATTENUATED INFLUENZA VACCINE (LAIV) IN CHILDREN AGED 2–11 YEARS IN CATALONIA (SPAIN)


EPH101

COST-EFFECTIVENESS ANALYSIS OF EXPANDED INFLUENZA VACCINATION COVERAGE WITH LIVE ATTENUATED INFLUENZA VACCINE (LAIV) IN CHILDREN AGED 2–11 YEARS IN CATALONIA (SPAIN)

Why did we perform this research?

Summary

Expanding paediatric LAIV vaccination may reduce influenza burden:

186,896 children vaccinated

140,083 infections prevented

493 hospitalizations avoided

18 deaths prevented

The healthcare system could save €3.8 million while improving health outcomes

Key takeaway

In Catalonia, expanding LAIV vaccination to children aged 5–11 years was a dominant strategy, delivering better health outcomes while generating cost savings from both public health system and societal perspectives.

How did we perform this research?

What did we find?

Sensitivity analyses confirmed the results' robustness

What are the implications for payers?

Acknowledgments

Disclosures

References

Robles-Plaza M, Prats C, Soriano-Arandes A, Antón A, de Pedro S, Oyagüez I, Capel Sanchez M, Rubín A, Sánchez G